Novartis stock heads into the open after a 1.3% Swiss slip
Published on 09/07/2026 at 07:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 4, 2026, Novartis stock finished at CHF 129.58 on the Swiss Exchange, down 1.33%. The decline outpaced the broader Swiss market, where the main index also slipped over the same session according to the Swiss market overview at MarketScreener. Early today, Novartis highlighted Phase III topline results for its pelacarsen cardiovascular study, which frame sentiment heading into the open.
September 4, 2026 in numbers
Novartis AG (ISIN CH0012005267) closed the last completed session on the Swiss Exchange at CHF 129.58 on September 4, 2026, a drop of 1.33% from the previous close as reported in the Swiss equities summary at MarketScreener. The same data showed the five-day performance at plus 4.72%, indicating that despite the latest setback the shares remained higher on a week-to-date basis. The session came amid broader weakness in Swiss blue chips, with the Swiss market barometer also in negative territory in the same closing overview. In parallel trading of the company’s US-listed shares, Novartis American depositary shares carried a last closing level of USD 160.05 in the Swiss equities factors piece, underscoring the cross-market valuation backdrop.
Market commentary around the move pointed to clinical trial news on pelacarsen, a lipoprotein(a) lowering therapy being developed with Ionis Pharmaceuticals, as a key focus for traders. A MarketBeat wrap detailed how Novartis and Ionis disclosed that pelacarsen failed to reduce major cardiovascular events in a Phase III outcome study, while still noting earlier positive sentiment around other pipeline assets. The same MarketBeat analysis also flagged that Novartis shares trading in New York were down about 1.9% in the latest session, giving a consistent picture of moderate pressure across venues. Together, the trial disappointment and the soft tone in the Swiss equity market helped shape Novartis’s risk profile at the end of the week.
Today’s catalysts around September 7, 2026
Today, Novartis is back in the news flow with fresh clinical data communication that investors may weigh against the prior pelacarsen setback. A company press release on September 7, 2026 sets out Phase III topline results for the Lp(a)HORIZON program, detailing the cardiovascular outcomes picture for pelacarsen and outlining the next regulatory and commercial steps; this update is summarized in the topline announcement available via the company’s news distribution partner. In addition, regional partnership activity continues, with South Korean outlet Seoul Economic Daily reporting on September 7, 2026 that Yuhan has entered a strategic agreement with Novartis Korea covering distribution and promotion of the hives treatment Rhapsido, adding a commercial dimension to the day’s headlines. Broader market conditions are shaped by the North American calendar, where major US exchanges remain closed on September 7, 2026 for the Labor Day holiday according to the week-ahead schedule at BNN Bloomberg, potentially dampening cross-border trading volumes in Novartis until US markets reopen.
